Nexthera Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nexthera Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-8,250	Closed	-$733K	–	25
2019 Q1	$733K	Buy	+8,250	New	+$765K	0.89%	23
2018 Q2	–	Sell	-259,235	Closed	-$22.7M	–	48
2018 Q1	$21M	Buy	259,235 +95,238	+58%	+$8.17M	3.46%	4
2017 Q4	$14.6M	Buy	163,997 +44,336	+37%	+$3.86M	2.7%	11
2017 Q3	$11.1M	Buy	119,661 +18,861	+19%	+$1.67M	2.86%	8
2017 Q2	$9.15M	Buy	+100,800	New	+$9.17M	3.99%	12

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Nexthera Capital's BMRN Position: Q2 2019 in Review

Nexthera Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 8,250 shares — an estimated $733K sold.

Nexthera Capital first reported a position in BMRN in Q2 2017 and held it in 5 quarters. The position peaked at $21M in Q1 2018. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Nexthera Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Nexthera Capital sold 8,250 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $733K.
Nexthera Capital first reported a position in BioMarin Pharmaceuticals in Q2 2017 and held it in 5 quarters.
Nexthera Capital's BioMarin Pharmaceuticals position peaked at $21M in Q1 2018.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.